Mural Oncology plc (NASDAQ:MURA) Short Interest Down 15.7% in October

Mural Oncology plc (NASDAQ:MURA) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 392,800 shares, a decline of 15.7% from the September 30th total of 465,800 shares. Approximately 2.5% of the shares of the stock are sold short. Based on an average daily volume of 94,200 shares, the days-to-cover ratio is currently 4.2 days.

Mural Oncology Price Performance

Shares of MURA traded up $0.08 during mid-day trading on Monday, reaching $3.59. 2,095 shares of the company’s stock traded hands, compared to its average volume of 186,205. The stock has a market cap of $60.76 million and a P/E ratio of -0.34. The stock’s 50-day moving average is $3.32 and its two-hundred day moving average is $3.41. Mural Oncology has a 12 month low of $2.88 and a 12 month high of $17.00.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.90) by $0.04. Research analysts predict that Mural Oncology will post -7.59 earnings per share for the current year.

Institutional Trading of Mural Oncology

A number of large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Mural Oncology in the second quarter valued at approximately $98,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Mural Oncology during the second quarter worth $84,000. Armistice Capital LLC purchased a new stake in Mural Oncology during the second quarter worth $5,300,000. Squarepoint Ops LLC purchased a new stake in Mural Oncology during the second quarter worth $526,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Mural Oncology during the second quarter worth $70,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Raymond James assumed coverage on Mural Oncology in a research report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 target price on the stock. HC Wainwright started coverage on Mural Oncology in a research note on Thursday, October 17th. They set a “buy” rating and a $18.00 price objective on the stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.